UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Cell reports (Cambridge), 2018-12, Vol.25 (11), p.3074-3085.e5

2018

Volltextzugriff (PDF)

Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim

Proceedings of the National Academy of Sciences - PNAS, 2009-04, Vol.106 (14), p.5663-5668

2009

Volltextzugriff (PDF)

Analysis of the Innate Response to Adjuvants: Characterization of the Draining Lymph Node by Fluorescence-Activated Cell Sorting

Methods in molecular biology (Clifton, N.J.), 2017-01, Vol.1494, p.305

Desbien, Anthony L

2017

Volltextzugriff (PDF)

Recombinant Listeria promotes tumor rejection by CD8⁺ T cell-dependent remodeling of the tumor microenvironment

Proceedings of the National Academy of Sciences - PNAS, 2018-08, Vol.115 (32), p.8179-8184

2018

Volltextzugriff (PDF)

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL‐18, and IFN‐γ

European journal of immunology, 2015-02, Vol.45 (2), p.407-417

2015

Volltextzugriff (PDF)

IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants

The Journal of immunology (1950), 2016-12, Vol.197 (11), p.4351-4359

2016

Volltextzugriff (PDF)

MyD88 and TRIF synergistic interaction is required for TH1‐cell polarization with a synthetic TLR4 agonist adjuvant

European journal of immunology, 2013-09, Vol.43 (9), p.2398-2408

2013

Volltextzugriff (PDF)

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors

Cancer immunology research, 2018-04, Vol.6 (4), p.422-433

2018

Volltextzugriff (PDF)

Comment on "The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele"

The Journal of immunology (1950), 2017-06, Vol.198 (11), p.4183-4185

2017

Volltextzugriff (PDF)

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Cell reports (Cambridge), 2019-10, Vol.29 (3), p.785-789

2019

Volltextzugriff (PDF)

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization

Journal of controlled release, 2014-03, Vol.177, p.20-26

2014

Volltextzugriff (PDF)

TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses

Vaccine, 2013-12, Vol.31 (49), p.5848-5855

2013

Volltextzugriff (PDF)

Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses

BioTechniques, 2013-06, Vol.54 (6), p.345-348

2013

Volltextzugriff (PDF)

Abstract 1445: STING activation in the tumor microenvironment with a synthetic human STING-activating cyclic dinucleotide leads to potent anti-tumor immunity

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1445-1445

2016

Volltextzugriff (PDF)

Abstract SY39-02: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.SY39-02-SY39-02

2016

Volltextzugriff (PDF)

Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals

AIDS research and human retroviruses, 2008-11, Vol.24 (11), p.1415

2008

Volltextzugriff (PDF)

Mechanisms of activity of the combination TLR4 agonist and emulsion adjuvant GLA-SE

The Journal of immunology (1950), 2016-05, Vol.196 (1_Supplement), p.75-75.2

2016

Volltextzugriff (PDF)

Antigen presentation by B cells guides programing of memory CD4 super(+) T-cell responses to a TLR4-agonist containing vaccine in mice

European journal of immunology, 2016-12, Vol.46 (12), p.2719-2729

2016

Volltextzugriff (PDF)

Antigen presentation by B cells guides programming of memory CD4 T cell responses to a TLR4-agonist containing vaccine

European journal of immunology, 2016-11, Vol.46 (12), p.2719-2729

2016

Volltextzugriff (PDF)

Recombinant Listeria promotes tumor rejection by CD8^sup +^ T cell-dependent remodeling of the tumor microenvironment

Proceedings of the National Academy of Sciences - PNAS, 2018-08, Vol.115 (32), p.8179

2018

Volltextzugriff (PDF)

The TLR4 agonist vaccine adjuvant, GLA-SE, requires canonical and atypical mechanisms of action for TH1 induction

The Journal of immunology (1950), 2016-05, Vol.196 (1_Supplement), p.75-75.7

2016

Volltextzugriff (PDF)

Abstract 631: Intratumoral activation of STING with a synthetic cyclic dinucleotide elicits antitumor CD8 T-cell immunity that effectively combines with checkpoint inhibitors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.631-631

2018

Volltextzugriff (PDF)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T.sub.H1 Induction

PloS one, 2016-01, Vol.11 (1)

2016

Volltextzugriff (PDF)

Abstract PR09: ADU-S100 (MIW815) synergizes with checkpoint blockade to elicit an antitumor CD8+ T-cell response to control distal tumors

Cancer immunology research, 2020-04, Vol.8 (4_Supplement), p.PR09-PR09

2020

Volltextzugriff (PDF)

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-[gamma]

European journal of immunology, 2015-02, Vol.45 (2), p.407

2015

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(29)

Sprache

Englisch
(29)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Life Sciences & Biomedicine
(13)
Animals
(9)
Immunology
(9)
Mice
(9)
Female
(6)
Humans
(4)
Mice, Inbred C57bl
(4)
Mice, Knockout
(4)
Toll-Like Receptor 4 - Agonists
(4)
Adjuvants, Immunologic - Pharmacology
(3)
B-Lymphocytes - Immunology
(3)
Emulsions
(3)
Signal Transduction - Drug Effects
(3)
T-Lymphocytes - Immunology
(3)
Th1 Cells - Immunology
(3)
Tlr4
(3)
Toll-Like Receptor 4 - Immunology
(3)
Vaccines
(3)
Adjuvant
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim

Analysis of the Innate Response to Adjuvants: Characterization of the Draining Lymph Node by Fluorescence-Activated Cell Sorting

Recombinant Listeria promotes tumor rejection by CD8⁺ T cell-dependent remodeling of the tumor microenvironment

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL‐18, and IFN‐γ

IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants

MyD88 and TRIF synergistic interaction is required for TH1‐cell polarization with a synthetic TLR4 agonist adjuvant

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors

Comment on "The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele"

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization

TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses

Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses

Abstract 1445: STING activation in the tumor microenvironment with a synthetic human STING-activating cyclic dinucleotide leads to potent anti-tumor immunity

Abstract SY39-02: Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity

Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals

Mechanisms of activity of the combination TLR4 agonist and emulsion adjuvant GLA-SE

Antigen presentation by B cells guides programing of memory CD4 super(+) T-cell responses to a TLR4-agonist containing vaccine in mice

Antigen presentation by B cells guides programming of memory CD4 T cell responses to a TLR4-agonist containing vaccine

Recombinant Listeria promotes tumor rejection by CD8^sup +^ T cell-dependent remodeling of the tumor microenvironment

The TLR4 agonist vaccine adjuvant, GLA-SE, requires canonical and atypical mechanisms of action for TH1 induction

Abstract 631: Intratumoral activation of STING with a synthetic cyclic dinucleotide elicits antitumor CD8 T-cell immunity that effectively combines with checkpoint inhibitors

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T.sub.H1 Induction

Abstract PR09: ADU-S100 (MIW815) synergizes with checkpoint blockade to elicit an antitumor CD8+ T-cell response to control distal tumors

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-[gamma]

Suchergebnisse filtern